100% total lies and gibberish. Also DCVax-L is not the same as ATLDC. NWBO is not a sponsor of the UCLA combo trials and has no shared benefit. UCLA combo trials are also still in very early stages. A phase 3 trial would be required, which would take at least 5 years and 300 or more patients to render statistical relevant data.
Facts:
While both UCLA's ATL-DC (autologous tumor lysate-pulsed dendritic cell vaccine) and DCVax-L (autologous tumor lysate-loaded dendritic cell vaccine) employ fundamentally similar approaches—using a patient's own dendritic cells loaded with tumor lysate to stimulate an immune response against glioblastoma—they are not identical.
Key differences include:Development and Branding: ATL-DC refers to the vaccine platform developed and tested in UCLA-led trials (e.g., the Phase II study NCT01204684 by Dr. Linda Liau and colleagues). DCVax-L is the proprietary name for a similar vaccine developed by Northwest Biotherapeutics, with Dr. Liau as a key collaborator and lead investigator in its Phase III trial (NCT00045968).
Adjuvant Use: In the UCLA Phase II study, ATL-DC was combined with the TLR agonist poly-ICLC (or resiquimod) as an immune-boosting adjuvant, which polarized interferon responses and contributed to improved outcomes (median OS of 52.5 months in the poly-ICLC arm across 9 patients with mixed newly diagnosed and recurrent high-grade gliomas). DCVax-L in its Phase III trial did not incorporate poly-ICLC or a similar adjuvant, focusing solely on the dendritic cell vaccine added to standard-of-care temozolomide, yielding a median OS of 19.3 months from randomization in newly diagnosed GBM patients.
Trial Contexts and Outcomes: The ATL-DC + poly-ICLC combination showed promising results in smaller cohorts, with superior survival compared to vaccine alone (e.g., 47% 3-year survival in combined treatment vs. 20% without adjuvant in related analyses). DCVax-L's larger trial extended survival modestly (13% 5-year survival vs. 5.7% historical), but without the adjuvant enhancement seen in UCLA's ATL-DC protocols. The ongoing Phase I trial (NCT04201873) specifically uses ATL-DC + poly-ICLC with Keytruda (pembrolizumab), further differentiating it from DCVax-L's standalone approach.
These variations in adjuvants and trial designs mean the methods, while overlapping in core technology, differ in execution and potential efficacy. Ongoing research continues to refine these immunotherapies.
Market Data 
Markets 
AI
